Ketamine Infusion for Adolescent Depression and Anxiety

Randomised, quadruple-blind, crossover trial in adolescents with medication-refractory major depressive disorder or anxiety disorders (actual N=17). Participants received a single IV infusion of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) with a 2-week washout between sessions.

Primary outcomes are change in MADRS score (MDD cohort) and change in MASC acute physical symptoms subscale (anxiety cohort) at 1 day post-infusion; safety/tolerability monitored during infusion and for hours afterwards.